Nuvisan

Nuvisan is a private, full-service Science CRO/CDMO offering integrated drug discovery and development solutions from target identification to clinical phases. Its service portfolio spans discovery (omics, screening, pharmacology, chemistry), preclinical (DMPK, safety), clinical (Phase I/II, bioanalysis), CMC, and digital sciences including AI/ML. The company leverages its pharma heritage and scientific expertise to de-risk and accelerate client programs, with a focus on therapeutic areas like oncology and dermatology. As a service provider, its business model is fee-for-service, generating revenue through client contracts.

Integrated CRO/CDMO service platform encompassing discovery sciences, preclinical & clinical development, CMC, and a dedicated Digital sciences division utilizing machine learning, generative AI, cheminformatics, bioinformatics, and molecular modeling.

Nuvisan competes in the fragmented but consolidating global CRO/CDMO market. Key competitors range from large full-service players (e.g., IQVIA, Charles River Laboratories, LabCorp) to specialized preclinical, clinical, or CMO firms. Its differentiation is based on deep scientific expertise, integrated service offerings, and a strong focus on digital and AI-enabled solutions.